Daniel O’Day, in his eight months on the job as CEO of Gilead Sciences, has faced a single, persistent question: What are you going to buy?
“People are worried about the cash in our pocket,” O’Day said with a grin at the STAT Summit on Wednesday. And Gilead, which had about $25 billion in cash at the end of the last quarter, is “in an acquisitive mode,” he said.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,